For Patients

Antibody-Drug Conjugates

An antibody-drug conjugate is an antibody that is attached to a cytotoxic chemotherapy drug. Antibodies target certain proteins such as those of bacteria or other foreign substances, but can also be created to specifically target the surface of cancer cells. The antibodies used in Adcendo’s ADCs have been designed to recognize specific proteins which can be found on the surface of certain cancer cells in the body, thereby delivering the attached cytotoxic chemotherapy directly into the cancer cell.
By targeting these specific proteins, it is hoped that the cancer cells are hit whilst avoiding normal cells, with the aim of treating the cancer effectively while limiting side effects.

ADCE-T02

Adcendo’s first clinical-stage antibody-drug conjugate, ADCE-T02, targets Tissue Factor (TF), which is a protein found in high amounts in numerous cancers.
A first-in-human trial called Tiffany-01 is currently ongoing in patients with advanced cancer. Further information about the Tiffany-01 trial can be found via the link on the right-hand side of this page.

ADCE-D01

Adcendo’s antibody-drug conjugate ADCE-D01 targets uPARAP, a protein found in high amounts in mesenchymal cancers such as soft tissue sarcoma.
A first-in-human trial called ADCElerate1 is currently ongoing in patients with soft tissue sarcoma (STS[RC2.1]). Further information about the ADCElerate1 trial can be found via the link on the right-hand side of this page.

ADCE-B05

ADCE-B05 is a novel ADC (target undisclosed) being developed for squamous cell tumors. A first-in-human trial is currently ongoing in patients with advanced solid tumors with squamous characteristics. Further information about the Galapagos 01 trial can be found via the link on the right-hand side of this page.